id: off_label_aud_medications_to_alcohol_consumption_reduction
name: Off-Label AUD Medications Access â†’ Reduction in Alcohol Consumption
from_node:
  node_id: off_label_aud_medications
  node_name: Off-Label AUD Medications Access
to_node:
  node_id: alcohol_consumption_reduction
  node_name: Reduction in Alcohol Consumption
direction: negative
category: healthcare_access
mechanism_pathway:
- 'Step 1: Off-label medications (gabapentin, baclofen, topiramate) modulate neurotransmitter
  systems dysregulated by chronic alcohol use'
- 'Step 2: Neurochemical modulation reduces alcohol craving, withdrawal symptoms,
  and reinforcement'
- 'Step 3: Symptom reduction and decreased reinforcement support reduced alcohol consumption'
- 'Step 4: When accessible and prescribed, off-label medications provide additional
  treatment options for AUD'
evidence:
  quality_rating: C
  n_studies: 3
  primary_citation: 'Henry R Kranzler and Emily E Hartwell 2023. "Medications for
    treating alcohol use disorder: A narrative review.." *Alcohol, clinical & experimental
    research*. https://doi.org/10.1111/acer.15118'
last_updated: '2025-12-02'
version: '1.0'
llm_metadata:
  extracted_by: claude-sonnet-4-5-20250929
  extraction_date: '2025-12-02T18:12:06.671675'
  batch_id: msgbatch_01AKnPJgzm7Fk9qubgAz9GaD
moderators:
- name: insurance_coverage
  direction: strengthens
  strength: strong
  description: Off-label medication coverage by insurance is highly variable and may
    significantly limit access compared to FDA-approved options
- name: provider_knowledge
  direction: strengthens
  strength: moderate
  description: Provider familiarity and comfort with off-label prescribing for AUD
    affects medication availability
